Really as good as could be expected, Phase 2 trials like this have no statistical significance due to the tiny number of people in the trial so the main outcome is the safety one.
People will inevitably read to much into the results not understanding statistics, but the main takeaway is that safety outcomes justify moving to Phase 2b so its still a live project.
I think we will see the SP settle back to the mid to low 30's now, once again waiting for confirmation that the business has moved from a speccy biotech to a sustainably profitable business.
Pre-login to the webinar, page-21
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |